Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 182

1.

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, Rabin N, Kurman M, Novak B, Shiraishi N, Nakashima D, Akinaga S, Yong K.

Br J Cancer. 2017 Sep 5. doi: 10.1038/bjc.2017.302. [Epub ahead of print]

PMID:
28873084
2.

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia is not Improved by Concurrent Vorinostat Therapy but is Predicted by a Diagnostic Molecular Signature.

Craddock C, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai S, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P.

Clin Cancer Res. 2017 Aug 1. pii: clincanres.1423.2017. doi: 10.1158/1078-0432.CCR-17-1423. [Epub ahead of print]

PMID:
28765326
3.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.

Leukemia. 2017 May 26. doi: 10.1038/leu.2017.159. [Epub ahead of print]

PMID:
28546581
4.

British Committee for Standards in Haematology guidelines for aplastic anemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of 20 × 109 /L - RESPONSE to Yan et al.

Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JCW; British Society for Standards in Haematology AA Guidelines Committee.

Br J Haematol. 2017 May 23. doi: 10.1111/bjh.14766. [Epub ahead of print] No abstract available.

PMID:
28542907
5.

Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree.

Tawana K, Wang J, Király PA, Kállay K, Benyó G, Zombori M, Csomor J, Al Seraihi A, Rio-Machin A, Matolcsy A, Chelala C, Cavenagh J, Fitzgibbon J, Bödör C.

Eur J Hum Genet. 2017 Aug;25(8):1020-1024. doi: 10.1038/ejhg.2017.80. Epub 2017 May 17.

PMID:
28513614
6.

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.

Subramanian J, Cavenagh J, Desai B, Jacobs I.

Cancer Manag Res. 2017 Apr 24;9:131-140. doi: 10.2147/CMAR.S120589. eCollection 2017. Review.

7.

Long-term stabilisation of myeloma with curcumin.

Zaidi A, Lai M, Cavenagh J.

BMJ Case Rep. 2017 Apr 16;2017. pii: bcr2016218148. doi: 10.1136/bcr-2016-218148.

PMID:
28413157
8.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

9.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK.

Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.

10.

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.

Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.

Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.

PMID:
27843120
11.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.

N Engl J Med. 2016 Oct 6;375(14):1319-1331.

12.

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group.

Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.

PMID:
27374467
13.

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.

Brown S, Hinsley S, Ballesteros M, Bourne S, McGarry P, Sherratt D, Flanagan L, Gregory W, Cavenagh J, Owen R, Williams C, Kaiser M, Low E, Yong K; Myeloma UK Clinical Trials Network.

BMC Hematol. 2016 May 17;16:14. doi: 10.1186/s12878-016-0053-9. eCollection 2016.

14.

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.

Burnett A, Cavenagh J, Russell N, Hills R, Kell J, Jones G, Nielsen OJ, Khwaja A, Thomas I, Clark R; UK NCRI AML Study Group.

Haematologica. 2016 Jun;101(6):724-31. doi: 10.3324/haematol.2016.141937. Epub 2016 Feb 26.

15.

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.

Parrish C, Morris CT, Williams CD, Cairns DA, Cavenagh J, Snowden JA, Ashcroft J, Cavet J, Hunter H, Bird JM, Chalmers A, Brown JM, Yong K, Schey S, Chown S, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1009-16. doi: 10.1016/j.bbmt.2016.01.016. Epub 2016 Jan 28.

16.

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.

Yong K, Cavet J, Johnson P, Morgan G, Williams C, Nakashima D, Akinaga S, Oakervee H, Cavenagh J.

Br J Cancer. 2016 Jan 12;114(1):7-13. doi: 10.1038/bjc.2015.422. Epub 2015 Dec 22.

17.

Guidelines for the diagnosis and management of adult aplastic anaemia.

Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC; British Society for Standards in Haematology.

Br J Haematol. 2016 Jan;172(2):187-207. doi: 10.1111/bjh.13853. Epub 2015 Nov 16. No abstract available. Erratum in: Br J Haematol. 2016 Nov;175(3):546.

PMID:
26568159
18.

Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.

Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T.

J Med Econ. 2016;19(3):243-58. doi: 10.3111/13696998.2015.1115407. Epub 2015 Nov 17.

PMID:
26517601
19.

Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J.

Blood. 2015 Sep 3;126(10):1214-23. doi: 10.1182/blood-2015-05-647172. Epub 2015 Jul 10.

20.

Malignant causes of fever of unknown origin.

Foggo V, Cavenagh J.

Clin Med (Lond). 2015 Jun;15(3):292-4. doi: 10.7861/clinmedicine.15-3-292.

PMID:
26031983

Supplemental Content

Loading ...
Support Center